Welcome to our dedicated page for Neuraxis news (Ticker: $NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neuraxis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neuraxis's position in the market.
Rhea-AI Summary
NeurAxis, a medical technology company, announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with a Blue Cross Blue Shield licensee in North Dakota. This expands coverage for IB-Stim™ to approximately 16.5 million individuals, highlighting the strength of the clinical data and the company's focus on market adoption of their technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. (NRXS) reported strong operational highlights, including a 300% increase in total covered lives to 16 million individuals. The company's PENFS technology showed significant improvements in pediatric patients with gut-brain disorders. Results from studies on IB-Stim therapy for adolescents with abdominal pain were positive. NeurAxis also signed an exclusive option agreement for an innovative rectal expulsion device and secured $6.1 million in financing. CEO Brian Carrico is optimistic about future revenue growth and expansion of medical policy coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. to Report Q4 and Fiscal Year 2023 Financial Results; Files Form NT 10-K with SEC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
Rhea-AI Summary
NeurAxis, a medical technology company, announced positive results from a multicenter study on IB-Stim for pediatric gut-brain interaction disorders. The study showed significant improvements in gastrointestinal symptoms and functionality, with 92% of patients having failed medication therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. announces policy coverage from Highmark Blue Cross Blue Shield for approximately 7 million lives, expanding total covered lives to 16.25 million. The company focuses on neuromodulation therapies for chronic conditions. CEO Brian Carrico highlights doubling covered lives since last year and aims for national expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
Rhea-AI Summary
NeurAxis, a medical technology company, receives policy coverage from Blue Cross and Blue Shield of Kansas City for approximately one million lives, expanding their total covered lives to 9.25 million. The company aims to leverage clinical evidence for market adoption of their neuromodulation therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
Rhea-AI Summary
NeurAxis, a medical technology company, will participate in the Oppenheimer Healthcare Conference to present their neuromodulation therapies for chronic conditions. The event will take place on March 12, 2024, offering investors insights into the company's advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. appoints Timothy Henrichs as Chief Financial Officer, bringing over 20 years of global leadership experience across various industries. The company will issue 100,000 shares of common stock to Mr. Henrichs as an inducement to become an employee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. (NYSE American: NRXS) has issued a letter to its shareholders detailing significant developments over the past 4 months and the future outlook for the company. The company has achieved strong data publications leading to broad insurance policy coverage and exponential revenue growth. NeurAxis has secured numerous large insurance policy coverages, leading to an increase in revenues. Additionally, the company is anticipating two new revenue opportunities in 2024, including FDA clearance for Functional Dyspepsia for children and an exclusive licensing agreement with the University of Michigan for a chronic constipation device. NeurAxis is confident in surpassing its target of 75M covered lives by the end of 2024 and expects substantial revenue growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
Rhea-AI Summary
NeurAxis, Inc. (NRXS) reported Q3 2023 financial results, including a retrospective comparative study on adolescents with functional abdominal pain disorders (FAPD). The study showed that IB-Stim™ therapy was more effective than standard medications in improving abdominal pain and functional disability. The company also announced progress in clinical evidence expansion, exclusive option agreement with the University of Michigan, $3 million in financing, and policy coverage from CareFirst BCBS, among other achievements. Despite a decrease in revenue, the gross margin remained strong at 85.9%. However, the net loss increased to ($4,904.4) thousand, or ($1.35) per common share, compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
Neuraxis, Inc.
NYSE:NRXS
NRXS Rankings
NRXS Stock Data
20.77M
1.91M
47.47%
1.53%
0.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
CARMEL